Safety, Tolerability, Pharmacokinetics & Target Engagement of ETH47 in Healthy Subjects
Time: 8:00 am
day: Day 2 AM
Details:
- Showcasing nasal administration of ETH47 development for the prevention of virusdriven exacerbation in patients with asthma
- Demonstrating data on safety and well tolerated and not systemically bioavailable in healthy trial participants
- Overall, results present a dose-dependent local target protein induction
